The stock of BioNTech SE ADR (BNTX) has seen a -5.56% decrease in the past week, with a -13.81% drop in the past month, and a -12.76% decrease in the past quarter. The volatility ratio for the week is 2.23%, and the volatility levels for the past 30 days are at 3.67% for BNTX. The simple moving average for the last 20 days is -13.77% for BNTX stock, with a simple moving average of -16.50% for the last 200 days.
Is It Worth Investing in BioNTech SE ADR (NASDAQ: BNTX) Right Now?
The price-to-earnings ratio for BioNTech SE ADR (NASDAQ: BNTX) is above average at 169.43x, Company’s 36-month beta value is 0.22.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BNTX is 237.14M, and currently, short sellers hold a 1.16% ratio of that floaft. The average trading volume of BNTX on June 27, 2024 was 729.16K shares.
BNTX) stock’s latest price update
The stock of BioNTech SE ADR (NASDAQ: BNTX) has decreased by -1.71 when compared to last closing price of 82.52. Despite this, the company has experienced a -5.56% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-27 that NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron JN.1-adapted monovalent COVID-19 vaccine (COMIRNATY® JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition and the European Medicines Agency’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the SARS-CoV-2 variant JN.1 for the 2024-2025 vaccination campaign. ETF stated that “evidence indicates that targeting JN.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.” 1, 2
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Evercore ISI repeating the rating for BNTX by listing it as a “In-line.” The predicted price for BNTX in the upcoming period, according to Evercore ISI is $100 based on the research report published on May 14, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $127. The rating they have provided for BNTX stocks is “Outperform” according to the report published on February 23rd, 2024.
BNTX Trading at -12.09% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.54% of loss for the given period.
Volatility was left at 3.67%, however, over the last 30 days, the volatility rate increased by 2.23%, as shares sank -12.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.87% lower at present.
During the last 5 trading sessions, BNTX fell by -5.37%, which changed the moving average for the period of 200-days by -31.10% in comparison to the 20-day moving average, which settled at $93.46. In addition, BioNTech SE ADR saw -23.15% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.17 for the present operating margin
- 0.47 for the gross margin
The net margin for BioNTech SE ADR stands at 0.04. The total capital return value is set at -0.02. Equity return is now at value 0.54, with 0.49 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 24.26. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17.52.
Currently, EBITDA for the company is 1.16 billion with net debt to EBITDA at -158.05. When we switch over and look at the enterprise to sales, we see a ratio of 3.42. The receivables turnover for the company is 1.42for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.38.
Conclusion
In a nutshell, BioNTech SE ADR (BNTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
